Author

Kevin Mohammed

Icahn School of Medicine at Mount SinaiORCID 0000-0002-9955-9407Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Ana Orive-RamosiD· 1 shared Beau BaarsiD· 1 shared Bijaya GaireiD· 1 shared Christos AdamopoulosiD· 1 shared Ernesto GuccioneiD· 1 shared Evangelia MatenoglouiD· 1 shared Evripidis GavathiotisiD· 1 shared Jian Jun JiniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ana Orive-RamosORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition

Ana Orive-Ramos, Bijaya Gaire, Christos Adamopoulos, Beau Baars, Mathieu Desaunay, Ziyue Kou, Evangelia Matenoglou, Sílvia Coma, Nayeli Gutiérrez, Kevin Mohammed, Stuart A. Aaronson, Jian Jun Jin, Tiphaine C. Martin, Ernesto Guccione, Evripidis Gavathiotis, , Poulikos I. Poulikakos

The paper shows RAF/MEK glues enable full-dose combination with pan-RAF inhibitors, enhancing tumor-selective MAPK inhibition and tumor regression in RAS-mutant models.

Cancer Discovery · Sep 29, 2026Peer-reviewedCancer Biology